Fathom Therapeutics, formerly Atommap Corp., secured an oversubscribed Series A financing round of 47 million dollars led by Sutter Hill Ventures, with participation from Chemistry, Alexandria Venture Investments, and NY Ventures. The company specializes in applying quantum chemistry and artificial intelligence to design novel small-molecule drugs by predicting their behavior within living cells, leveraging a proprietary platform called Microcosmos.
This engine uses physics-based simulations and proprietary algorithms to model protein motion at atomic resolution, accelerating protein dynamics modeling by “10,000x without compromising accuracy” and enabling generative design of molecules that reshape protein behavior for targeted therapeutic effects. Microcosmos has already guided discovery and optimization efforts across multiple target classes and modalities; in one example, it produced potent, highly selective degraders against an “undruggable” target in six weeks, which are now being optimized for clinical advancement.
The leadership team, founded by Huafeng Xu (CEO), Yujie Wu (CTO), and Jesús Izaguirre (Chief Computational Scientist), brings extensive experience in molecular modeling and drug discovery, including work on the Anton supercomputer and widely used protein–drug binding software. New funding will support scaling lab-in-the-loop capabilities, expanding internal discovery programs in high-impact diseases, and strengthening an active pipeline and external discovery partnerships, with the team having collectively advanced 19 drugs to the clinic, including seven approved by the FDA.
The company also reinforced its governance and scientific depth by appointing Mandana Honu as Chief Business Officer, adding biotech entrepreneur Diala Ezzeddine to the board, and establishing a Scientific Advisory Board composed of prominent experts from industry and academia. Headquartered in New York with a second office in Boston, Fathom Therapeutics aims to build a continuous “flywheel” for small-molecule medicines that would be impossible to create using traditional drug discovery approaches.
Referencia
Atommap Corporation. (2026, April 27). Fathom Therapeutics, formerly Atommap, raises $47 million in oversubscribed Series A financing to translate physics and AI-enabled small molecule design into next-generation medicines. PR Newswire. https://www.prnewswire.com/news-releases/fathom-therapeutics-formerly-atommap-raises-47-million-in-oversubscribed-series-a-financing-to-translate-physics-and-ai-enabled-small-molecule-design-into-next-generation-medicines-302754272.html